Mitozolomide

Mitozolomide
Clinical data
ATC code	none;
Identifiers
	IUPAC name 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide;
CAS Number	85622-95-3 ;
PubChem CID	71766;
ChemSpider	64805 ;
UNII	E3U7286V3W;
ChEMBL	ChEMBL435951 ;
CompTox Dashboard (EPA)	DTXSID40234862 ;
ECHA InfoCard	100.079.921
Chemical and physical data
Formula	C7H7ClN6O2
Molar mass	242.62 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)c1ncn2C(=O)N(CCCl)\N=N/c12;
	InChI InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15) ; Key:QXYYYPFGTSJXNS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

References

Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther. 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631. S2CID 2597751.
Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer. 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719. PMID 1739631.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.